Gregory Adams

Gregory Adams is a highly experienced professional in the field of cancer therapeutics, currently serving as a Scientific Advisory Board Member at Integral Molecular since June 2015. Previously, Gregory held significant leadership roles, including Chief Scientific Officer at Elucida Oncology, Inc. until June 2024, where development of targeted nanoparticle Drug Conjugates was a focus, and at Sesen Bio from September 2016 to March 2019, overseeing antibody-based fusion proteins aimed at treating cancer. Gregory's extensive background also includes serving as Chief Development Officer at Viventia Bio Inc. for 15 years, and various academic roles at Fox Chase Cancer Center, including Adjunct Associate Professor and Director of Biological Research and Therapeutics. Gregory earned a Ph.D. in Immunology from the University of California, Davis, and a B.A. in Biology from the University of California, Santa Cruz.